Effectiveness Of Cancer Drug Tied To New Gene Mutation

October 23, 2008

Scientists have come out and stated that they have linked a second gene mutation to the effectiveness of the bowel cancer drugs Erbitux and Vectibix..............Washington (ChattahBox) – Scientists have come out and stated that they have linked a second gene mutation to the effectiveness of the bowel cancer drugs Erbitux and Vectibix.

At a medical meeting in Geneva, researchers revealed the two gene mutations to the public.

The two cancer drugs in question here include Erbitux by ImClone, and sold by Bristol-Myers Squibb and Merk,  as well as Vectibix from Amgen.

They have found that the effectiveness of these two cancer drugs depends on gene mutations.

The new mutation discovered is known as BRAF, but is not as prominent as the KRAS mutation.

The KRAS mutation was discovered in 40% of cases where the drugs did not work on patients.

This was built on with the find of the BRAF mutation, which was found in 12% of the patients who failed to respond to the medicine.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.